Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28493942 | 0.90 | ADORA1 (0.58) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28491901 | 0.82 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL28499708 | 0.78 | ADORA2A (0.48) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28491887 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28499042 | 0.74 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL28505779 | 0.74 | ADORA2A (0.62) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2323913 | 0.72 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL28491044 | 0.71 | ADORA2A (0.59) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28905138 | 0.71 | ADORA2A (0.58) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28505688 | 0.71 | ADORA2A (0.52) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108467386-B | Fused heteroaryl substituted 1,2, 4-triazine-3-amine derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-11-17 | — | — | CN | disclosed |